Sandoz announces agreement to acquire CIMERLI® business from Coherus
资讯
2024-01-22
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
MEDIA RELEASE
CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for ...